MONOCLONAL ANTIBODY OF NERVE GROWTH FACTOR, AND ENCODING GENE AND USE THEREOF

Abstract

The present invention discloses a monoclonal antibody against nerve growth factor, and an encoding gene and use thereof. The monoclonal antibody against nerve growth factor of the present invention comprises heavy chains comprising a heavy chain constant region and a heavy chain variable region, and light chains comprising a light chain constant region and a light chain variable region. The heavy chain variable region comprises three complementarity determining regions HCDR1, HCDR2 and HCDR3, and the light chain variable region comprises three complementarity determining regions LCDR1, LCDR2 and LCDR3. The monoclonal antibody against nerve growth factor of the present invention can specifically bind to nerve growth factor, and can be used to detect the presence and/or level of nerve growth factor, as well as to prepare a drug for inhibiting the nerve growth factor-dependent proliferation of TF-1 cells, and to prepare a drug for treating or preventing at least one of neuropathic pain, chronic pain, and inflammatory pain, thus having good application prospects and marketing value.

Claims

1. A monoclonal antibody against nerve growth factor, comprising heavy chains comprising a heavy chain constant region and a heavy chain variable region, and light chains comprising a light chain constant region and a light chain variable region, wherein the heavy chain variable region comprises three complementarity determining regions HCDR1, HCDR2 and HCDR3, and the light chain variable region comprises three complementarity determining regions LCDR1, LCDR2 and LCDR3; the amino acid sequence of the complementarity determining region HCDR1 is set forth in SEQ ID NO: 5; the amino acid sequence of the complementarity determining region HCDR2 is set forth in SEQ ID NO: 6; the amino acid sequence of the complementarity determining region HCDR3 is set forth in SEQ ID NO: 7; the amino acid sequence of the complementarity determining region LCDR1 is set forth in SEQ ID NO: 8; the amino acid sequence of the complementarity determining region LCDR2 is set forth in SEQ ID NO: 9; and the amino acid sequence of the complementarity determining region LCDR3 is set forth in SEQ ID NO: 10.

2. The monoclonal antibody against nerve growth factor according to claim 1, wherein the amino acid sequence of the heavy chain variable region is set forth in SEQ ID NO: 2; the amino acid sequence of the light chain variable region is set forth in SEQ ID NO: 4.

3. The monoclonal antibody against nerve growth factor according to claim 1, wherein the monoclonal antibody against nerve growth factor is selected from a Fab, a Fab′, an F(ab′).sub.2, an Fd, an Fv, a dAb, a complementarity determining region fragment, a single chain antibody, a humanized antibody, a chimeric antibody, and a diabody.

4. The monoclonal antibody against nerve growth factor according to claim 1, wherein the monoclonal antibody against nerve growth factor binds to NGF protein with an EC.sub.50 of less than 100 nM.

5. A nucleotide sequence encoding the monoclonal antibody against nerve growth factor according to claims 1 or 2.

6. The nucleotide sequence according to claim 5, wherein the nucleotide sequence encoding the heavy chain variable region is set forth in SEQ ID NO: 1; and the nucleotide sequence encoding the light chain variable region is set forth in SEQ ID NO: 3.

7. A vector, comprising the nucleotide sequence according to claims 5 or 6.

8. A host cell, comprising the nucleotide sequence according to claims 5, 6, or 7.

9. A monoclonal antibody conjugate, comprising the monoclonal antibody against nerve growth factor according to claims 1 or 2, and a conjugated portion conjugated thereto, wherein the conjugated portion is a detectable label.

10. A kit, comprising the monoclonal antibody against nerve growth factor according to claims 1 or 2 and/or the monoclonal antibody conjugate according to claim 9.

11. The kit according to claim 10, further comprising a secondary antibody specifically recognizing the monoclonal antibody against nerve growth factor according to claims 1 or 2.

12. Use of the monoclonal antibody against nerve growth factor according to claims 1 or 2 and/or the monoclonal antibody conjugate according to claim 9 in preparing a kit for detecting the presence and/or level of nerve growth factor.

13. Use of the monoclonal antibody against nerve growth factor according to claims 1 or 2 and/or the monoclonal antibody conjugate according to claim 9 in preparing: a drug that specifically binds to nerve growth factor; a drug that inhibits the proliferation of nerve growth factor-dependent TF-1 cells; and/or a drug for treating or preventing at least one of neuropathic pain, chronic pain, and inflammatory pain.

14. A drug, comprising the monoclonal antibody against nerve growth factor according to claims 1 or 2 and/or the monoclonal antibody conjugate according to claim 9 as an active ingredient, and a pharmaceutically acceptable carrier or excipient.

15. The drug according to claim 14, wherein the drug specifically binds to nerve growth factor to inhibit nerve growth factor-dependent proliferation of TF-1 cells, and/or to treat or prevent at least one of neuropathic pain, chronic pain, and inflammatory pain.

Description

BRIEF DESCRIPTION OF DRAWINGS

[0048] FIG. 1 shows the SDS-PAGE analysis results of the monoclonal antibody H26L17 against nerve growth factor of the present invention. The samples of the four lanes from left to right and respective loading amounts thereof are: antibody in non-reduced protein electrophoresis loading buffer, 1 μg; antibody in reduced protein electrophoresis loading buffer, 1 μg; protein molecular weight marker (Marker), 5 μL; bovine serum albumin (BSA), 1 μg.

[0049] FIG. 2 shows the analysis results of the binding activity of H26L17 and Tanezumab to the antigen human R-NGF.

[0050] FIG. 3 shows the standard curve results for the analysis of H26L17 and Tanezumab inhibition on TF-1 cell proliferation by the CCK-8 method.

[0051] FIG. 4 shows the cell quantity after 72 h of inhibition of NGF-induced TF-1 cell proliferation by the monoclonal antibody H26L17 against nerve growth factor of the present invention.

[0052] FIG. 5 shows the OD value of each group in measuring the inhibition of TF-1 cell proliferation by H26L17 and Tanezumab by the CCK-8 method.

[0053] FIG. 6 shows the fitting curve of H26L17 inhibiting NGF-induced TF-1 cell proliferation. Taking the logarithm of antibody concentration (nM) as the x-axis and the OD 450 nm value as the y-axis, dose-effect curve fitting was performed to compare the EC.sub.50 of different antibodies.

[0054] FIG. 7 shows the effect of H26L17 on the walking behavior of the affected limb caused by pain in the knee arthritis pain model of Lenti-IL-1β-NIH/3T3 mice.

[0055] FIG. 8 shows the effect of H26L17 on the weight of mice in the knee arthritis pain model of Lenti-IL-1β-NIH/3T3 mice.

DETAILED DESCRIPTION

[0056] The embodiments of the present invention will be described in detail below with reference to the examples. Those skilled in the art will understand that the following examples are only used to illustrate the present invention, and should not be regarded as limiting the scope of the present invention. The cases without the specific descriptions of techniques or conditions were carried out according to the technologies or conditions described in the literature in the art (e.g., see, Guide to Molecular Cloning Experiments, authored by J. Sambrook et al., and translated by Huang Peitang et al., third edition, Science Press) or according to the product manual. Reagents or instruments used are commercially available conventional products if the manufacturers thereof are not specified.

[0057] In the following examples of the present invention, C57BL/6 mice used were purchased from Guangdong Medical Experimental Animal Center.

[0058] The positive control antibody Tanezumab used was Pfizer antibody Tanezumab (David L. Shelton. Methods for treating bone cancer by administering a Nerve Growth Factor antagonist antibody. USA, 20110243961A1. 2011-06-06).

Example 1. Design, Expression and Purification of H26L17 Heavy Chain and Light Chain Sequences

[0059] 1. Design of Antibody

[0060] In order to generate anti-human NGF antibody H26L17, the inventors creatively designed a series of antibody sequences based on the NGF protein sequence and three-dimensional crystal structure thereof, etc. Through extensive screening and analyses, an antibody, H26L17, that specifically binds to NGF was finally obtained. The amino acid sequences of the heavy chain variable region and the light chain variable region of the antibody and the encoding DNA sequences thereof are set forth in SEQ ID NOs: 1-4.

[0061] 2. Expression and Purification of Antibody

[0062] The encoding nucleotide sequence of the heavy chain variable region (set forth in SEQ ID NO: 1; the constant region is Ig gamma-1 chain C region, ACCESSION: P01857) and the encoding nucleotide sequence of the light chain variable region (set forth in SEQ ID NO: 3; the constant region is Ig lambda-2 chain C region; ACCESSION: P0CG05.1) of H26L17 were independently cloned into pUC57 simple vectors (provided by Genscript), and pUC57simple-H26L17H and pUC57simple-H26L17L plasmids were obtained respectively.

[0063] The plasmids pUC57simple-H26L17H and pUC57simple-H26L17L were digested (HindIII & EcoRI), and the nucleotide sequences of the heavy chain and light chain recovered by electrophoresis were independently subcloned into pcDNA3.1 vectors, and the recombinant plasmids were extracted to co-transfect 293F cells. After the transfected 293F cells were cultured for 7 days, the culture medium was centrifuged at high speed, and the obtained supernatant was concentrated and loaded onto a HiTrap MabSelect SuRe column. The protein was eluted in one step with the eluent to isolate the target sample. The antibody sample was stored in PBS buffer.

[0064] The purified sample was added to both a reduced protein electrophoresis loading buffer and a non-reduced protein electrophoresis loading buffer, and then boiled. The processed samples were analyzed by SDS-PAGE electrophoresis. The electropherogram of H26L17 is shown in FIG. 1. The target protein sample in the reduced buffer is at 45 kD and 30 kD, and the target protein sample in the non-reduced buffer (single antibody) is at 150 kD.

[0065] The H26L17 prepared in this example was used in the following examples 2 to 4.

Example 2. Analysis of the Binding Activity of H26L17 to the Antigen Human β-NGF

[0066] In this experiment, the ELISA method was used to determine the EC.sub.50 (median effect concentration) of H26L17 binding to human β-NGF to investigate the binding specificity and affinity of the antibody to human β-NGF.

[0067] A microplate was coated with 50 L of 0.5 μg/mL human β-NGF in each well, and incubated overnight at 4° C. After the microplate was washed once and patted dry, each well was blocked with 300 L of 1% BSA solution (dissolved in PBS). The microplate was incubated at 37° C. for 2 h, and patted dry after being washed three times. The antibody was diluted to 1 μg/mL as the initial concentration, and a 1:3 gradient dilution was performed in the microplate to obtain a total of 7 concentrations, in addition to a blank control well. Duplicate wells were set for the above concentrations, with a final volume of 100 μL per well, and the microplate was incubated at 37° C. for 30 min. After the microplate was washed three times and patted dry, 50 μL of horseradish peroxidase-labeled goat anti-human IgG (H+L) secondary antibody working solution was added to each well, and the microplate was incubated at 37° C. for 30 min. After the microplate was washed four times and patted dry, 50 μL of TMB chromogenic solution was added to each well for color developing at room temperature for 5 min in the absence of light, then 50 μL of stop solution was added to each well to stop the color developing reaction. Immediately after the reaction was terminated, the microplate was placed in a microplate reader, and 450 nm light wavelength was selected to read the OD value of each well of the microplate. SoftMax Pro 6.2.1 software was used to analyze and process the data.

[0068] It can be seen from Table 2 and FIG. 2 that the 450 nm reading results show that H26L17 can effectively bind to human β-NGF, and the binding efficiency is dose-dependent. Taking the antibody concentration as the abscissa and the absorbance value as the ordinate, a 4-parameter fitting curve was plotted, resulting in a binding EC.sub.50 of 0.071 nM, comparable to that of Tanezumab. See Table 2 for the analysis results of the binding activity of H26L17 and Tanezumab to human β-NGF. The results show that the binding of H26L 17 to the antigen human j-NGF is dose-dependent, with a binding EC.sub.50 of 0.071 nM, comparable to Tanezumab.

TABLE-US-00001 TABLE 2 The analysis results of the binding activity of H26L17 and Tanezumab to the antigen human β-NGF Antibody Antigen-antibody binding OD (450 nm) value dilution H26L17 Tanezumab 1 μg/mL 2.730 2.655 2.770 2.705 1:3  2.704 2.797 2.656 2.553 1:9  2.663 2.605 2.482 2.274 1:27 2.242 2.222 2.166 1.969 1:81 1.613 1.525 1.178 1.266  1:243 0.779 0.735 0.560 0.609  1:729 0.323 0.313 0.227 0.245 0 0.047 0.046 0.044 0.045 EC.sub.50 (nM) 0.071 0.103

Example 3. Analysis of Cell Biological Activity of H26L17

[0069] 1. Analysis of the Pharmacological Activity of H26L17 in Inhibiting NGF-Induced TF-1 Cell Proliferation

[0070] In order to analyze the effect of H26L17 in inhibiting NGF-dependent TF-1 cell proliferation, antibodies, NGF and TF-1 cells of different concentrations were co-incubated and the cell proliferation was measured after 72 h of culturing. The specific procedures are as follows:

[0071] TF-1 cells were collected by centrifugation and counted, and 40,000 cells were seeded in each well of a 96-well plate. For administration, the control group was set with three NGF concentrations: 0.2, 2, and 20 ng/mL, and the antibody group was set with 20 ng/mL NGF; the antibody was set with five concentrations: 0.016 nM, 0.08 nM, 0.4 nM, 2 nM, and 10 nM. Before administering the NGF/antibody premix to cells, the antibody and NGF were pre-incubated at 37° C. for 30 min. In the experiment, an isotype control group was also included. After the cells were cultured for 72 h (pipetted and homogenized once every 24 h) post treatment, cell proliferation was measured according to the instructions of the CCK-8 test kit (100 μL of liquid was taken for analysis). The standard curve of cell proliferation is shown in FIG. 3. The analysis results of cell proliferation after 72 h of cell incubation are shown in FIG. 4. As seen in FIG. 4, H26L17 inhibits the stimulation effect of NGF on TF-1 cell proliferation in a dose-dependent manner. In particular, when the antibody concentration is lower than 0.08 nM, the H26L17 antibody is significantly better than the positive control antibody Tanezumab in inhibiting the effect of NGF on TF-1 cell proliferation.

[0072] 2. EC.sub.50 Value of H26L17 Neutralizing NGF in the Experiment of H26L17 Inhibiting NGF-Induced TF-1 Cell Proliferation

[0073] To analyze the pharmacological activity of H26L17 in inhibiting NGF-induced TF-1 cell proliferation and calculate the EC.sub.50 of H26L17 neutralizing NGF, antibodies, NGF and TF-1 cells of different concentrations were co-incubated and the cell proliferation was measured after 72 h of culturing. The specific procedures or methods are briefly described as follows:

[0074] TF-1 cells were collected by centrifugation and seeded in a 96-well plate with 40,000 cells per well. For administration, the control group was set with three NGF concentrations: 0.06 nM, 0.3 nM, and 1.5 nM. The final concentration of NGF in the NGF/antibody premix group was 1.5 nM, and the concentrations of antibodies were 0.0468 nM, 0.07 nM, 0.105 nM, 0.158 nM, 0.237 nM, 0.356 nM, 0.533 nM, and 0.8 nM, respectively. Before administering the NGF/antibody premix to cells, the antibody and NGF were pre-incubated at 37° C. for 30 min. In the experiment, an isotype antibody control group with a concentration of 1.5 nM was included. After the cells were cultured for 72 h (pipetted and homogenized once every 24 h) post treatment, cell proliferation was measured according to the instructions of the CCK-8 test kit (100 μL of liquid was taken for analysis).

[0075] The OD values of each group measured in the CCK-8 experiment are shown in FIG. 5. Taking the logarithm of antibody concentration (nM) as the x-axis and the OD 450 nm value as the y-axis, the dose-effect curve fitting was performed to compare the EC.sub.50 of different antibodies, and the fitting curve is shown in FIG. 6. H26L17 can inhibit the NGF-induced TF-1 cell proliferation in a dose-dependent manner, showing a neutralizing activity against NGF, and the activity is slightly better than that of the marketed drug Tanezumab for the same target. The neutralizing EC.sub.50 to NGF of the two are 0.16 nM and 0.21 nM, respectively, and the H26L17 antibody is significantly better than the positive control antibody Tanezumab in inhibiting the effect of NGF on TF-1 cell proliferation.

Example 4. H26L17 can Improve the Walking Behavior of the Affected Limb and Alleviate the Weight Loss in the Knee Arthritis Pain Model of Lenti-IL-1β-NIH/3T3 Mice

[0076] Patients with arthritis would experience lameness and other behavioral changes due to pain, as well as weight loss resulted from reduced food intake due to bad emotions induced by the pain. In order to measure the alleviation of anti-NGF antibody to knee arthritis pain response, a mouse model of knee arthritis pain induced by Lenti-IL-1β-NIH/3T3 was established, and the drug efficacy was evaluated by behavioral improvement of mice. In this model, Lenti-IL-1β-NIH/3T3 cells overexpressed IL-1β in the joint cavity of mice, which in turn induced joint inflammation and pain at the injection site. In this experiment, 60 C57BL/6 mice were divided into 6 groups according to body weight, namely normal group (saline, S.C.), model group (anti-HEL, 20 mg/kg, S.C.), Tanezumab group (Tanezumab, 20 mg/kg, S.C.) and H26L17 antibody low-dose group (H26L17, 0.2 mg/kg, S.C.), medium-dose group (H26L17, 2 mg/kg, S.C.), and high-dose group (H26L17, 20 mg/kg, S.C.), 10 animals per group. The day of grouping was recorded as day 0 (D0). After grouping, the mice were weighed, and the corresponding drugs were injected subcutaneously according to the mouse body weight at an administration volume of 10 mL/kg. The drugs were administered three times in total, and were administered subcutaneously on D0, D3, and D6 respectively after grouping. After administration on the day of grouping, 10 C57BL/6 mice in the normal group were inoculated with NIH/3T3 cell suspension (50,000 cells/mouse) in the knee joint cavity, and the other 50 C57BL/6 mice in the remaining groups were inoculated with Lenti-IL-1β-NIH/3T3 cell suspension (50,000 cells/mouse) in the knee joint cavity. Then behavioral scoring of mice was conducted on D3, D5 and D11 after administration on the day of grouping.

[0077] The results of the effect of anti-NGF antibody on the knee joint pain response in mice are shown in FIG. 7. Compared with the positive control antibody Tanezumab (20 mg/kg, S.C.), the H26L17 high-dose group (20 mg/kg, S.C.) reduces pain response significantly; compared with the positive control antibody Tanezumab (20 mg/kg, S.C.), the H26L17 antibody low-dose group (0.2 mg/kg, S.C.) and the H26L17 medium-dose group (2 mg/kg, S.C.) have equivalent effect in reducing pain in mice. The results of anti-NGF antibody alleviating the weight loss of mice in the mouse knee arthritis pain model are shown in FIG. 8. The H26L17 antibody medium and high dose groups have equivalent effect as the positive control antibody Tanezumab in alleviating the weight loss of mice in the mouse knee arthritis pain model, more significant than the isotype control anti-HEL.

[0078] The preferred embodiments of the present invention have been described above in detail, but the present invention is not limited to the embodiments. Those skilled in the art can make various equivalent modifications or replacements without violating the spirit of the present invention. These equivalent modifications or replacements are included in the scope defined by the claims of the present application.